26 This study showed a trend toward fewer VGPRs in patients with CXCR4 mutations.
← all excerpts
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
1
—
—
26 This study showed a trend toward fewer VGPRs in patients with CXCR4 mutations.